Form 4: Bristol-Myers Squibb Executive Amanda Poole Ahn Reports Changes in Beneficial Ownership

EVP, Chief People Officer of Bristol-Myers Squibb, Amanda Poole Ahn, reports transactions involving common stock and market share/performance units.

Summary

• Amanda Poole Ahn, EVP, Chief People Officer of Bristol-Myers Squibb, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• The reported transactions include the vesting of market share units and performance shares, as well as the withholding of shares for tax payments.
• These transactions occurred on March 10, 2025.
• Ahn's direct holdings of common stock changed due to vesting and tax withholdings, while her indirect holdings through the BMS Savings and Investment Program remain at 172,361 shares.
• She also acquired and disposed of derivative securities, specifically market share units and performance shares, which convert into common stock based on performance factors.

Sentiment

Score: 6

Explanation: The document is a routine filing related to executive compensation. It doesn't contain any particularly positive or negative news, but the vesting of shares suggests that performance targets were met.

Positives

• The vesting of market share units and performance shares indicates that certain performance targets were met, which is a positive sign for the company's performance.
• The executive's continued holding of a significant number of shares in the company demonstrates confidence in its future prospects.

Negatives

• The withholding of shares for tax payments reduces the number of shares directly held by the executive.

Risks

• The value of market share units and performance shares is dependent on the company's stock price and performance, which are subject to market risks.
• Changes in the company's performance or market conditions could affect the payout factor and the ultimate value of these units.

Future Outlook

The document mentions future vesting and distribution of market share units and performance shares in 2028, subject to performance results.

Industry Context

Executive compensation and stock ownership are common practices in the pharmaceutical industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among publicly traded companies, including pharmaceutical giants like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK).
• The specific terms of market share units and performance shares, such as payout factors and vesting schedules, can vary significantly between companies.
• Benchmarking against industry peers would require a detailed analysis of their executive compensation plans.

Stakeholder Impact

• The vesting of shares and the executive's ownership stake can influence investor confidence.
• Executive compensation practices can impact employee morale and perception of fairness.

Next Steps

• Future vesting and distribution of market share units and performance shares in 2028, subject to performance results.

Key Dates